Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

NCT01017575 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Infection

Interventions

DRUG: Daclatasvir
DRUG: Daclatasvir
DRUG: Placebo
DRUG: Peginterferon alfa-2a
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb